Association Between Dosage Frequency and the Treatment Outcomes of Sildenafil in Young and Middle-aged Men With Erectile Dysfunction: A Chinese, Multicenter, Observational Study.

作者: Yi Yang , Ruizhi Liu , Hui Jiang , Kai Hong , Lianming Zhao

DOI: 10.1016/J.UROLOGY.2015.03.011

关键词:

摘要: Objective To evaluate the correlation between dosage frequency of sildenafil and its treatment outcomes in men with erectile dysfunction (ED). Methods Data were from a 4-week, multicenter, observational study (1699), 18 60 years age, clinical diagnosis ED defined as Sexual Health Inventory for Men (SHIM) score ≤21. The function quality sexual life evaluated at baseline endpoint (after 4 weeks) by using SHIM, Self-Esteem Relationship Questionnaire, 36-Item Short Form Survey, Erection Hardness Score, global efficacy question. Results Nine hundred thirty-five patients enrolled the ≤1 weekly, 573 2-3 158 4-7 weekly cohorts. After 4 weeks treatment, higher was associated better Survey score improvement (all P  = .04), whereas hypertension (odds ratio, 0.25; .05) are sensitive to treatment. Conclusion Higher is ED, concomitant hyperlipidemia recommended.

参考文章(30)
Joo Hyun Lee, Ju-Hee Oh, Young-Joo Lee, Effects of Experimental Hyperlipidemia on the Pharmacokinetics of Tadalafil in Rats Journal of Pharmacy & Pharmaceutical Sciences. ,vol. 15, pp. 528- 537 ,(2012) , 10.18433/J35P59
John P. Mulhall, Irwin Goldstein, Andrew G. Bushmakin, Joseph C. Cappelleri, Kyle Hvidsten, ORIGINAL RESEARCH—OUTCOMES ASSESSMENT: Validation of the Erection Hardness Score The Journal of Sexual Medicine. ,vol. 4, pp. 1626- 1634 ,(2007) , 10.1111/J.1743-6109.2007.00600.X
Abdulla Al Naimi, Ahmad A. Majzoub, Raidh A. Talib, Onder Canguven, Abdulla Al Ansari, Erectile Dysfunction in Qatar: Prevalence and Risk Factors in 1,052 Participants—A Pilot Study Sexual Medicine. ,vol. 2, pp. 91- 95 ,(2014) , 10.1002/SM2.26
JinQiu Yuan, RenJie Zhang, ZuYao Yang, Jack Lee, YaLi Liu, JinHui Tian, XiWen Qin, ZhengJia Ren, Hong Ding, Qing Chen, Chen Mao, JinLing Tang, Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis European Urology. ,vol. 63, pp. 902- 912 ,(2013) , 10.1016/J.EURURO.2013.01.012
F Dadkhah, M R Safarinejad, M A Asgari, S Y Hosseini, A Lashay, E Amini, Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. International Journal of Impotence Research. ,vol. 22, pp. 51- 60 ,(2010) , 10.1038/IJIR.2009.48
TODD M. MOORE, JENNIFER L. STRAUSS, STEVE HERMAN, CRAIG F. DONATUCCI, Erectile dysfunction in early, middle, and late adulthood: symptom patterns and psychosocial correlates. Journal of Sex & Marital Therapy. ,vol. 29, pp. 381- 399 ,(2003) , 10.1080/00926230390224756
J C Cappelleri, S E Althof, R L Siegel, A Shpilsky, S S Bell, S Duttagupta, Development and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction. International Journal of Impotence Research. ,vol. 16, pp. 30- 38 ,(2004) , 10.1038/SJ.IJIR.3901095
José M Martínez-Jabaloyas, Manuel Gil-Salom, Rafael Villamón-Fort, Francisco Pastor-Hernández, Roberto Martínez-García, Francisco García-Sisamón, Prognostic Factors for Response to Sildenafil in Patients with Erectile Dysfunction European Urology. ,vol. 40, pp. 641- 647 ,(2001) , 10.1159/000049850